Peter Nowell is known for his discovery that a small terminal deletion on chromosome 22 is a consistent feature in leukemic cells from chronic myelogenous leukemia (CML) patients. This was the first direct evidence that a human cancer could be the result of a somatic (chromosomal) mutation, and paved the way for the development of a therapy that now cures 95% of individuals with CML.